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Abstract  
We present a 103 - year - old patient, with duration of complaints of about ten years. The initial complaint had 
been presented as a small nodule, located on the eyebrow, which subsequently ulcerated and encompassed 
larger regions of the upper and lower eyelids. For the past three years, the patient also had complaints of a 
worsening of his vision, without seeking for medical help. Within the dermatological examination, an intraocular 
and periocular localised tumour was established, characterised by a raised peripheral edge and central ulceration. 
More careful examination revealed that the bulb was fully consumed. The patient refused further diagnosis and 
treatment. Advanced basal cell carcinomas with intraocular invasion are rare in general. If the patient refuses 
surgery, radiotherapy and systemic therapy with modern medications such as Vismodegib or Sonidegib are 
available as treatment options. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Basal cell tumours can be easily treated in 
their early stages [1]. However, with the larger tumour 
growth, the more extensive treatment is needed [1]. 
Some special locations (eyelids, nose flap, lips, 
auricle) pose a challenge for the surgeon to remove 
the tumour entirely with proper margins and to retain 
functionality and satisfactory aesthetic appearance at 
the same time [1]. Furthermore, large, neglected 
tumours, especially located in the face region, 
demand complex reconstructive procedures after 
excision, i.e. local reconstruction techniques, free 
grafts, advanced, island, pedicle or microvascular 
flaps [1]. 
 
Case Report 
 
A 103 - year - old male patient, a peasant 
from the Bulgarian mountain region, presented with a 
reddish facial lesion. The reported complaints were 
from the last ten years. The lesion had occurred as a 
small papule on the medial part of the right eyebrow, 
followed by gradual enlargement and ulceration on a 
later stage, leading to complete loss of the upper 
eyelid (Fig. 1 a, b). The diagnosis of multicentric basal 
cell carcinoma (BCC) was made clinically and 
histopathologically. Any treatment was denied.  
Neglected patients are one of the major 
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contributing factors for the development of mutilating, 
horrifying and aggressive BCC - a rare, but potentially 
fatal cutaneous tumour [1]. Basal cell carcinoma 
occurs in the area of the head in 85 - 90% of cases, 
often above the line connecting the mouth corner with 
the ear lobe [2]. They are less often found in the lower 
part of the face and on the scalp [1]. 
 
Figure 1: A) 103-year-old male patient with oozing and crusted 
periocular lesion; B) Detail with loss of lids and eye 
 
 
Discussion 
 
In 10 - 15% of the cases, BCC is found on the 
neck, trunk and limbs. The affected area is commonly 
closely related to the exposure to ultraviolet radiation 
[3]. Although BCC could be rarely metastatic, it has a 
potential for tremendous and life - threating regional 
destruction in some locations, leading to severe 
disfigurations as in the presented case [1][2]. 
Two systemic treatments options that target 
the hedgehog pathway have become available 
recently for patients with advanced BCC: sonidegib 
(Odomzo; Novartis) and vismodegib (Erivedge; 
Roche). Based on results from a noncomparative 
study (the 200 mg arm of the BOLT trial) [3], sonidegib 
was approved recently in the United States and 
European Union for the treatment of adults with locally 
advanced BCC (laBCC) who are ineligible for curative 
surgery or radiotherapy [4][5]. Similarly, vismodegib is 
indicated for the treatment of adults with symptomatic 
metastatic BCC or adults with laBCC who are 
ineligible for surgery or radiotherapy, approved based 
on a single-arm trial (ERIVANCE) [6][7]. 
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